![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, an... Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The company's pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue. Show more
INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights PR Newswire PLYMOUTH MEETING, Pa., Aug. 8, 2024 PLYMOUTH MEETING, Pa., Aug. 8, 2024 /PRNewswire/ -- INOVIO...
INOVIO Reports Inducement Grant Under Inducement Plan PR Newswire PLYMOUTH MEETING, Pa., Aug. 1, 2024 PLYMOUTH MEETING, Pa., Aug. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology...
Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107 PR Newswire PLYMOUTH MEETING, Pa., July...
INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLYMOUTH MEETING, Pa., July 25, 2024 PLYMOUTH MEETING, Pa., July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO...
INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway PR Newswire PLYMOUTH MEETING, Pa., July 11, 2024 Award recognizes the...
INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer PR Newswire PLYMOUTH MEETING, Pa., July 2, 2024 Mr. Egge brings over 25 years of biopharmaceutical experience building...
INOVIO Reports Inducement Grant Under Inducement Plan PR Newswire PLYMOUTH MEETING, Pa., July 1, 2024 PLYMOUTH MEETING, Pa., July 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology...
INOVIO Added to Russell 2000® Index Effective July 1, 2024 PR Newswire PLYMOUTH MEETING, Pa., July 1, 2024 PLYMOUTH MEETING, Pa., July 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.36 | 4.33734939759 | 8.3 | 8.82 | 8.22 | 766847 | 8.55367604 | CS |
4 | -1.54 | -15.0980392157 | 10.2 | 11 | 8.22 | 837936 | 9.44564433 | CS |
12 | -2.71 | -23.8346525945 | 11.37 | 13.09 | 8.22 | 1138295 | 9.83219093 | CS |
26 | -1.24 | -12.5252525253 | 9.9 | 13.09 | 7.61 | 1058345 | 9.92904233 | CS |
52 | -4.5 | -34.1945288754 | 13.16 | 13.27 | 7.61 | 1167082 | 9.83886287 | CS |
156 | -33.34 | -79.380952381 | 42 | 58 | 7.61 | 1180982 | 22.50977973 | CS |
260 | -7.49 | -46.3777089783 | 16.15 | 141.01 | 7.61 | 1130857 | 29.50154694 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions